Literature DB >> 23017940

Clostridium difficile clinical isolates exhibit variable susceptibility and proteome alterations upon exposure to mammalian cationic antimicrobial peptides.

Rebecca McQuade1, Bryan Roxas, V K Viswanathan, Gayatri Vedantam.   

Abstract

Clostridium difficile is a leading cause of hospital-acquired bacterial infections in the United States, and the increased incidence of recurrent C. difficile infections is particularly problematic. The molecular mechanisms of C. difficile colonization, including its ability to evade host innate immune responses, is poorly understood. We hypothesized that epidemic-associated C. difficile clinical isolates would exhibit increased resistance to mammalian, gut-associated, cationic antimicrobial peptides such as the cathelicidin LL-37. Standardized susceptibility tests as well as comparative proteomic analyses revealed that C. difficile strains varied in their responses to LL-37, with epidemic-associated 027 ribotype isolates displaying greater resistance. Further, exposure of C. difficile strains to sub-lethal concentrations of LL-37 resulted in increased resistance to subsequent peptide challenge, suggesting the presence of inducible resistance mechanisms. Correspondingly, LL-37 exposure altered the C. difficile proteome, with marked changes in abundance of cell wall biosynthesis proteins, surface layer proteins, ABC transporters and lysine metabolism pathway components. Taken together, these results suggest that innate immune avoidance mechanisms could facilitate robust colonization by C. difficile. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23017940     DOI: 10.1016/j.anaerobe.2012.09.004

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  16 in total

1.  Synergistic effects of antimicrobial peptides and antibiotics against Clostridium difficile.

Authors:  Sabine Nuding; Tina Frasch; Martin Schaller; Eduard F Stange; Lutz T Zabel
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

Review 2.  Clostridium difficile infection.

Authors:  Wiep Klaas Smits; Dena Lyras; D Borden Lacy; Mark H Wilcox; Ed J Kuijper
Journal:  Nat Rev Dis Primers       Date:  2016-04-07       Impact factor: 52.329

3.  New role for human α-defensin 5 in the fight against hypervirulent Clostridium difficile strains.

Authors:  Lucinda Furci; Rossella Baldan; Valentina Bianchini; Alberto Trovato; Cristina Ossi; Paola Cichero; Daniela M Cirillo
Journal:  Infect Immun       Date:  2014-12-29       Impact factor: 3.441

4.  Characterization of Paeniclostridium sordellii Metalloproteinase-1 in vitro and in an experimental model of infection.

Authors:  John M French; Eric R McIndoo; Caden M Schlund; Kevin P Field; Alison R Wolfe; Dennis L Stevens; Michael J Aldape; Sarah E Hobdey
Journal:  Anaerobe       Date:  2021-10-22       Impact factor: 3.331

5.  The Clostridium difficile Protease Cwp84 Modulates both Biofilm Formation and Cell-Surface Properties.

Authors:  Véronique Pantaléon; Anna Philibertine Soavelomandroso; Sylvie Bouttier; Romain Briandet; Bryan Roxas; Michele Chu; Anne Collignon; Claire Janoir; Gayatri Vedantam; Thomas Candela
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

6.  A Clostridium difficile Cell Wall Glycopolymer Locus Influences Bacterial Shape, Polysaccharide Production and Virulence.

Authors:  Michele Chu; Michael J G Mallozzi; Bryan P Roxas; Lisa Bertolo; Mario A Monteiro; Al Agellon; V K Viswanathan; Gayatri Vedantam
Journal:  PLoS Pathog       Date:  2016-10-14       Impact factor: 6.823

7.  Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo.

Authors:  Bonita Durnaś; Ewelina Piktel; Marzena Wątek; Tomasz Wollny; Stanisław Góźdź; Jolanta Smok-Kalwat; Katarzyna Niemirowicz; Paul B Savage; Robert Bucki
Journal:  BMC Microbiol       Date:  2017-07-26       Impact factor: 3.605

Review 8.  Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections.

Authors:  Amoe Baktash; Elisabeth M Terveer; Romy D Zwittink; Bastian V H Hornung; Jeroen Corver; Ed J Kuijper; Wiep Klaas Smits
Journal:  Front Microbiol       Date:  2018-06-12       Impact factor: 5.640

Review 9.  The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent.

Authors:  Kylen E Ridyard; Joerg Overhage
Journal:  Antibiotics (Basel)       Date:  2021-05-29

Review 10.  Potential Use of Antimicrobial Peptides as Vaginal Spermicides/Microbicides.

Authors:  Nongnuj Tanphaichitr; Nopparat Srakaew; Rhea Alonzi; Wongsakorn Kiattiburut; Kessiri Kongmanas; Ruina Zhi; Weihua Li; Mark Baker; Guanshun Wang; Duane Hickling
Journal:  Pharmaceuticals (Basel)       Date:  2016-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.